About
Who we are
Co-founded by cognitive neurologist Dr. Étienne de Villers-Sidani (UCSF/McGill University), software engineer Yves Desgagné and neurologist Dr. Paul Giaccomini, INNODEM NEUROSCIENCES is a private company created in 2016 and backed by private investors. The company received FDA Breakthrough Device Designation for its ETNA-MS (Eye Tracking Neurological Assessment for Multiple Sclerosis) patented technology and received Health Canada clearance in early Q1-24 for their first product ETNA-MS, offering MS patients a non-invasive digital way to monitor the progression of their disease.
Preliminary clinical trial results have been peer-reviewed and are available in the publication Frontiers of Neurology. The company has already signed partnering agreements with Novartis Pharmaceuticals Canada Inc. including a commercial framework agreement. Other pharmaceutical partnership agreements are in the works and will be announced during the year.
What we do
Innodem Neurosciences is a digital biomarker & AI company that specializes in the development of an eye tracking technology, ETNA™, that shows promising use for neurological assessment of the progression of various neurological diseases. The ETNA™ technology is being trialed with patients living with various neurological diseases, such as multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Friedreich Ataxia, and cancer-related cognitive impairment.
Business Type / 業種
R&D / 研究開発Others / その他
Business Domain / 分野
Information technology / ITMedical devices / 医薬機器
Technologies / 技術
Digital Biomarkers / デジタルバイオマーカーPharmacological/Safety evaluation / 薬効・薬理・安全性評価
Disease Area/疾患領域
Neurology & Psychiatry/中枢神経、精神疾患
Additional Information
Requested business parter / ご希望のビジネスパートナー
Pharmaceuticals / 医薬品CRO /開発業務受託Neurology & Psychiatry/中枢神経、精神疾患Digital Biomarkers / デジタルバイオマーカー